Drug intelligence / Profile preview

empagliflozin + sacubitril + valsartan

Development stage: Preclinical
Lead developer: Althera Laboratories
Modality: Small Molecules
Administration: Oral

Overview

Empagliflozin + sacubitril + valsartan is a fixed-dose combination therapy developed by Althera Pharma for the treatment of heart failure. This oral small molecule combination integrates three complementary mechanisms of action: empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor; sacubitril, a neprilysin inhibitor; and valsartan, an angiotensin II type 1 (AT1) receptor blocker. By combining an SGLT2 inhibitor with an angiotensin receptor-neprilysin inhibitor (ARNI), the formulation aims to provide comprehensive neurohormonal modulation and metabolic benefits to improve cardiovascular outcomes, such as reducing the risk of cardiovascular death and hospitalization for heart failure, while simplifying the treatment regimen for patients.

Other names: Empagliflozin/Sacubitril/Valsartan 5/97/103Empagliflozin/Sacubitril/Valsartan 5/49/51Empagliflozin/Sacubitril/Valsartan 5mg/24mg/26mg

Targets

NEP (Neutral Endopeptidase)SGLT2 (Sodium-glucose cotransporter protein subunit 2)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on empagliflozin + sacubitril + valsartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on empagliflozin + sacubitril + valsartan.

Explore the full profile